Join Here   |   Log In

AMPD1 Deficiency: Post-exercise Muscle Soreness

Key takeaways:
~ The AMPD1 gene codes for an enzyme that converts AMP to IMP, which is particularly important for energy production in muscles during exercise.
~ A common AMPD1 gene variant can decrease this conversion, leading to fatigue and muscle soreness after exercise.
~ Tradeoffs. People with AMPD1 deficiency may experience increased muscle soreness, but it also is protective against heart disease.

Members will see their genotype report below and the solutions in the Lifehacks section. Consider joining today

AMPD1 gene (Adenosine monophosphate deaminase):

Adenosine monophosphate deaminase is an enzyme coded for by the gene AMPD1, which acts in the skeletal muscles to convert AMP to IMP. In a nutshell, AMPD1 is an enzyme that your muscles use when they need to make a lot of ATP for energy, such as when you are exercising. A common variant of the AMPD1 gene decreases the conversion, leading to a build-up of AMP.

One study explains:  “AMPD1 codes for the skeletal muscle isoform of myoadenylate deaminase (MAD). MAD promotes the deamination of adenosine monophosphate (AMP) to inosine monophosphate (IMP).”[ref]

This is all about energy production in the muscle, and AMPD1 is mainly expressed in fast-twitch muscle fibers. When it comes to exercise, people with decreased AMPD tend to get sore more easily after a hard workout. As one study puts it, people with the genetic variant that decreases AMPD get “muscle cramps, pain, and premature fatigue during exercise”.[ref]

Symptoms of AMPD1 deficiency:

AMPD1 deficiency, also known as myoadenylate deaminase deficiency, has varying effects on exercise performance, heart attack response, and methotrexate (cancer drug) response.

The main symptom of AMPD1 deficiency is that it causes sore muscles soon after a workout and sometimes muscle spasms when working out.[ref]

Prevalence of AMPD1 polymorphism:

A common AMPD1 genetic variant, known as C34T, causes a decrease in the function of this enzyme for people with one copy of the variant (heterozygous AMPD1 deficiency). This causes about a 60 – 84% decrease in enzyme activity.[ref]

People with two copies of this variant have a non-functioning enzyme. Caucasian and African populations carry one copy of the variant at a frequency of about 10%. It is much less frequent and rarely seen in other population groups, such as Asians.

Research studies on AMPD1 deficiency:

Exercise studies:

  • People with one copy (heterozygous) of the AMPD1 allele “require longer rest periods between bouts of weight training, require longer between sessions and have increased perceived pain post-training”.[ref]
  • In a study of elite triathlon athletes, AMPD1 was found to be the only significant genetic factor that negatively impacted performance time.[ref]
  • A study of Lithuanian athletes found that none of the athletes carried the AA genotype. Additionally, one copy of the variant likely affected anaerobic performance more than aerobic performance.[ref]
  • A study of elite rowers also found that the A allele was found much less often in the group.[ref]

Rheumatoid arthritis/methotrexate studies:

AMPD1 deficiency is associated with a good response to methotrexate in rheumatoid arthritis.[ref][ref]

Long Covid and lactic acid levels:

A study involving long Covid patients found that lactic levels were higher after exercise. Those with the AMPD1 deficiency genotype had the highest lactic acid levels post-exercise (Nordic walking) compared to the typical AMPD1 genotype. Interestingly, the AMPD1 deficiency genotype had a greater improvement in lactic acid levels by the end of the 12-week study (however, they were still higher than the typical genotype). One takeaway from this is that continuing to exercise gave a greater improvement to the AMPD1 deficiency group, but they were still well above both the control group and the long covid with normal genotype groups.[ref]

Heart Disease:

On the plus side, AMPD1 deficiency may be protective against heart disease.[ref]

  • A meta-study looked at the generally beneficial role of AMPD1 polymorphism in heart disease. The study showed that people with the A allele (see below) likely had better cardiac function.[ref]
  • Another study found that being heterozygous for the AMPD1 variant led to a better prognosis in cardiovascular disease.[ref]

AMPD1 Genotype Report:

Members: Log in to see your data below.
Not a member? Join here.


Access this content:

An active subscription is required to access this content.

Join as a member


Check out other Athletic Performance Genes and ACTN3


Lifehacks: Solutions for AMPD1 deficiency

Does AMPD1 deficiency mean that you can’t work out? Absolutely not!

Instead, it may mean that you want to modify the timing of your workout to decrease pain or muscle soreness. You may find that resting longer between weight-lifting sets in a workout helps, or that lower-intensity workouts may be better for you.

Supplements for AMPD1 deficiency:

Access this content:

An active subscription is required to access this content.

Join as a member



Related Articles and Topics:

Athletic Performance Genes

PPAR-Delta: Burning off the Fat


References:

Chen, Yuehong, et al. “Are Gene Polymorphisms Related to Treatment Outcomes of Methotrexate in Patients with Rheumatoid Arthritis? A Systematic Review and Meta-Analysis.” Pharmacogenomics, vol. 18, no. 2, Jan. 2017, pp. 175–95. PubMed, https://doi.org/10.2217/pgs-2016-0158.
Ciȩszczyk, P., et al. “Is the C34T Polymorphism of the AMPD1 Gene Associated with Athlete Performance in Rowing?” International Journal of Sports Medicine, vol. 32, no. 12, Dec. 2011, pp. 987–91. PubMed, https://doi.org/10.1055/s-0031-1283186.
Ginevičienė, Valentina, et al. “AMPD1 Rs17602729 Is Associated with Physical Performance of Sprint and Power in Elite Lithuanian Athletes.” BMC Genetics, vol. 15, May 2014, p. 58. PubMed Central, https://doi.org/10.1186/1471-2156-15-58.
———. “AMPD1 Rs17602729 Is Associated with Physical Performance of Sprint and Power in Elite Lithuanian Athletes.” BMC Genetics, vol. 15, May 2014, p. 58. PubMed, https://doi.org/10.1186/1471-2156-15-58.
Grealy, Rebecca, et al. “Evaluation of a 7-Gene Genetic Profile for Athletic Endurance Phenotype in Ironman Championship Triathletes.” PloS One, vol. 10, no. 12, 2015, p. e0145171. PubMed, https://doi.org/10.1371/journal.pone.0145171.
Lifanov, D., et al. “Effect of Creatine Supplementation on Physical Performance Are Related to the AMPD1 and PPARG Genes Polymorphisms in Football Players.” Rossiiskii Fiziologicheskii Zhurnal Imeni I.M. Sechenova, vol. 100, no. 6, June 2014, pp. 767–76.
Maestro, Antonio, et al. “Genetic Profile in Genes Associated with Muscle Injuries and Injury Etiology in Professional Soccer Players.” Frontiers in Genetics, vol. 13, Nov. 2022. Frontiers, https://doi.org/10.3389/fgene.2022.1035899.
Orphanet: Adenosine Monophosphate Deaminase Deficiency. https://www.orpha.net/en/disease/detail/45. Accessed 5 Feb. 2026.
Ramakers, Bart P, et al. “Circulating Adenosine Increases during Human Experimental Endotoxemia but Blockade of Its Receptor Does Not Influence the Immune Response and Subsequent Organ Injury.” Critical Care, vol. 15, no. 1, 2011, p. R3. PubMed Central, https://doi.org/10.1186/cc9400.
———. “Circulating Adenosine Increases during Human Experimental Endotoxemia but Blockade of Its Receptor Does Not Influence the Immune Response and Subsequent Organ Injury.” Critical Care, vol. 15, no. 1, 2011, p. R3. PubMed Central, https://doi.org/10.1186/cc9400.
Rannou, Fabrice, et al. “Effects of AMPD1 Common Mutation on the Metabolic-Chronotropic Relationship: Insights from Patients with Myoadenylate Deaminase Deficiency.” PLOS ONE, vol. 12, no. 11, Nov. 2017, p. e0187266. PLoS Journals, https://doi.org/10.1371/journal.pone.0187266.
Resistance Training, Recovery and Genetics: AMPD1 the Gene for Recovery. https://www.scitechnol.com/peer-review/resistance-training-recovery-and-genetics-ampd1-the-gene-for-recovery-rKtq.pdf. Accessed 5 Feb. 2026.
Smolenski, Ryszard T., et al. “AMP Deaminase 1 Gene Polymorphism and Heart Disease—A Genetic Association That Highlights New Treatment.” Cardiovascular Drugs and Therapy, vol. 28, no. 2, 2014, pp. 183–89. PubMed Central, https://doi.org/10.1007/s10557-013-6506-5.
Tarnopolsky, Mark A. “Clinical Use of Creatine in Neuromuscular and Neurometabolic Disorders.” Sub-Cellular Biochemistry, vol. 46, 2007, pp. 183–204. PubMed, https://doi.org/10.1007/978-1-4020-6486-9_10.
Wessels, Judith A. M., et al. “Relationship between Genetic Variants in the Adenosine Pathway and Outcome of Methotrexate Treatment in Patients with Recent-Onset Rheumatoid Arthritis.” Arthritis and Rheumatism, vol. 54, no. 9, Sept. 2006, pp. 2830–39. PubMed, https://doi.org/10.1002/art.22032.

About the Author:
Debbie Moon is a biologist, engineer, author, and the founder of Genetic Lifehacks where she has helped thousands of members understand how to apply genetics to their diet, lifestyle, and health decisions. With more than 10 years of experience translating complex genetic research into practical health strategies, Debbie holds a BS in engineering from Colorado School of Mines and an MSc in biological sciences from Clemson University. She combines an engineering mindset with a biological systems approach to explain how genetic differences impact your optimal health.